Esranur Aydın, Clinical Cancer Molecular Biologist at Medicana Health Group, shared a post on LinkedIn:

“New Publication!

I am delighted to share our latest paper titled ‘Navigating Uncharted Territory: A Case Report and Literature Review on the Remarkable Response to Personalized Crizotinib Containing Combinational Therapy in a Pazopanib Refractory Patient with Novel Alterations,’ published in Therapeutic Advances in Medical Oncology by SAGE.

In this paper, we delve into a captivating case showcasing the power of personalized and precision-oriented therapies in advanced cholangiocarcinoma management. Highlighting adaptability in diverse clinical settings and exploring less common genomic alterations, we underscore precision oncology’s dynamic nature.

Our findings emphasize the importance of molecular tumor boards and dosage adjustments, optimizing outcomes for patients with intricate genomic profiles. Additionally, we strengthen the evidence about synthetic lethality between crizotinib and CDH1 alterations, which further supports the translation of preclinical evidence into clinical settings.

As always, I want to extend my gratitude to our incredible team for their support Ünal Metin Tokat, Ashkan Adibi, Eylül Özgü , Şevval Nur Bilgiç Special thanks to Prof. Dr. Mutlu Demiray and Razelle Kurzrock for their invaluable guidance and support.  None of this would have been possible without your expertise and collaboration.

Let’s continue pushing the boundaries of medical research and making a difference in the lives of those battling cancer.”

Read further.
Source: Esranur Aydın/LinkedIn